NCT06546267Recruiting
Advanced Radiotherapy (ART) in Prostate Cancer (PROST-ART)
Efficacy of Advanced Radiotherapy (ART) in Prostate Cancer Patients With Early Stage, Advanced, Metastatic and Relapsed Disease (PROST-ART)
Source: ClinicalTrials.gov · Last updated 27 Oct 2026
Brief summary (registry, in English)
This is a retrospective monoinstitutional study which analyses the results of advanced radiotherapy (IGRT, IMRT, SBRT, and PET-guided) performed for radical, adjuvant, or salvage purposes in patients with low, intermediate, high, and very high-risk prostate cancer, or with biochemical, lymph node, or oligometastatic recurrence treated between 2004 and 2024. Approved by Ethics Committee of IRCCS San Raffaele Hospital Approval Number: 187/INT/2021, 03/02/2022 Amendment approved by Ethics Committee 1, Lombardy Region Approval number CET Em. 194-2024, 22/05/2024
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 2500 (estimated)
- First submitted
- 6 Aug 2024
- Start date
- 14 Feb 2022
- Primary completion date
- 14 Feb 2027
- Lead sponsor
- IRCCS San Raffaele
- Diseases
- Prostate cancer
- NCT number
- NCT06546267
What you commit to
- Study type: Observational
- Planned participants: 2500
- From 14 Feb 2022 to the primary completion date, 14 Feb 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Age
- \> 95 years old
Other
- other tumors
Who the study is looking for
- Prostate cancer patients, \> 18 years old, treated with IGRT, IMRT, SBRT
Age in the registry: 18 years to 95 years · Sex: Male
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| IRCCS San Raffaele Scientific Institute Coordinator of this site? Confirm its status | Milan | Italy | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.